PWM
TEVA icon

Perigon Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Perigon Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-85
Closed -$1K – 669
2017
Q3 		$1K Hold
85
– – ﹤0.01% 631
2017
Q2 		$3K Hold
85
– – ﹤0.01% 553
2017
Q1 		$3K Sell
85
-397
-82% -$13.5K ﹤0.01% 592
2016
Q4 		$17K Sell
482
-130
-21% -$5.19K ﹤0.01% 492
2016
Q3 		$28K Buy
+612
New +$31.9K 0.01% 361

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Perigon Wealth Management's TEVA Position: Q4 2017 in Review

Perigon Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 85 shares — an estimated $1K sold.

Perigon Wealth Management first reported a position in TEVA in Q3 2016 and held it in 5 quarters. The position peaked at $28K in Q3 2016. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Perigon Wealth Management reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Perigon Wealth Management sold 85 Teva Pharmaceuticals shares in Q4 2017, an estimated $1K.
  • Perigon Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • Perigon Wealth Management's Teva Pharmaceuticals position peaked at $28K in Q3 2016.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Perigon Wealth Management's 13F filing for Q4 2017, filed 14 Feb 2018.